Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Subscribe To Our Newsletter & Stay Updated